xtandi
astellas pharma europe b.v. - enzalutamide - prostata neoplasmer - endokrin terapi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
pevaryl 1 %
karo pharma ab (1) - ekonazolnitrat - pudder - 1 %
mezavant 1200 mg
takeda pharmaceuticals international ag ireland branch - mesalazin - enterodepottablett - 1200 mg
atorvastatin aristo 40 mg
aristo pharma gmbh - atorvastatinkalsiumtrihydrat - tablett, filmdrasjert - 40 mg
atorvastatin aristo 10 mg
aristo pharma gmbh - atorvastatinkalsiumtrihydrat - tablett, filmdrasjert - 10 mg
atorvastatin aristo 20 mg
aristo pharma gmbh - atorvastatinkalsiumtrihydrat - tablett, filmdrasjert - 20 mg
atorvastatin aristo 80 mg
aristo pharma gmbh - atorvastatinkalsiumtrihydrat - tablett, filmdrasjert - 80 mg
uvadex 20 mikrog/ ml
therakos europe ltd - metoksalen - oppløsning til blodfraksjonsmodifisering - 20 mikrog/ ml
lysodren
hra pharma rare diseases - mitotane - binyrebark i binyrebark - antineoplastiske midler - symptomatisk behandling av avansert (ikke-resekterbart, metastatisk eller tilbakefallende) binyrebarkert karsinom. effekten av lysodren på ikke-funksjonelle binyrebark carcinoma er ikke etablert.
pantoprazol sun 40 mg
sun pharmaceutical - nederland - pantoprazolnatriumsesquihydrat - pulver til injeksjonsvæske, oppløsning - 40 mg